Yahoo
ASX - Delayed Quote AUD

Medical Developments International Limited (MVP.AX)

0.3650 -0.0050 (-1.35%)
At close: October 30 at 4:10:11 PM GMT+11
Chart Range Bar
Loading chart for MVP.AX
  • Previous Close 0.3700
  • Open 0.3650
  • Bid 0.3700 x --
  • Ask 0.3800 x --
  • Day's Range 0.3650 - 0.3750
  • 52 Week Range 0.3650 - 0.7200
  • Volume 180,243
  • Avg. Volume 176,721
  • Market Cap (intraday) 41.12M
  • Beta (5Y Monthly) 1.56
  • PE Ratio (TTM) 36.50
  • EPS (TTM) 0.0100
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Mar 5, 2020
  • 1y Target Est 2.30

Medical Developments International Limited provides emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The company also supplies respiratory products, including space chambers, peak flow meters, portable nebulizers, and silicone face masks to aid sufferers of asthma and chronic obstructive pulmonary disease. Medical Developments International Limited was founded in 1972 and is headquartered in Scoresby, Australia.

medicaldev.com

--

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

MVP.AX
34.23%
S&P/ASX 200 [XJO] (^AXJO)
2.22%

1-Year Return

MVP.AX
47.86%
S&P/ASX 200 [XJO] (^AXJO)
0.29%

3-Year Return

MVP.AX
54.38%
S&P/ASX 200 [XJO] (^AXJO)
31.37%

5-Year Return

MVP.AX
92.48%
S&P/ASX 200 [XJO] (^AXJO)
21.63%

Analyst Insights

View More

Analyst Price Targets

1.00
2.30 Average
0.3650 Current
3.60 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.47%

  • Return on Assets (ttm)

    2.28%

  • Return on Equity (ttm)

    1.13%

  • Revenue (ttm)

    42.57M

  • Net Income Avi to Common (ttm)

    626k

  • Diluted EPS (ttm)

    0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    21.37M

  • Total Debt/Equity (mrq)

    2.99%

  • Levered Free Cash Flow (ttm)

    5.89M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: